炎症驱动药物代谢变异:HSCT受者伏立康唑治疗的启示
该回顾性研究分析126例HSCT患者中炎症与CYP2C19预测代谢表型对伏立康唑暴露及治疗窗达标的影响,发现剂量校正谷浓度与CYP2C19表型及CRP相关,炎症时浓度升高,尤其在中代谢者和快代谢者中超治疗浓度比例增加,提示应结合CRP加强TDM。
要点
- 炎症(CRP≥10 mg/L)与CYP2C19表型共同影响伏立康唑暴露。
- 炎症时中代谢者超治疗浓度33% vs 3%,快代谢者15% vs 0%。
- 中、快代谢者炎症期应加强TDM并同步评估CRP。
核心结论
- 炎症和CYP2C19基因型共同影响伏立康唑暴露及目标达标。
- 建议对中代谢和快代谢者炎症期加强TDM并同步评估CRP。
研究设计与样本
- 回顾性分析126例HSCT患者,采用线性混合模型评估剂量校正伏立康唑浓度与炎症及CYP2C19预测代谢表型的关联。
- 炎症定义为CRP≥10 mg/L。
主要发现
- 剂量校正伏立康唑谷浓度与CYP2C19预测代谢表型相关(LMM p=<2e-16;β=-5.99e-02-mg/L per mg voriconazole,SE=2.75e-02-mg/L per mg voriconazole,p=0.0315)。
- 剂量校正谷浓度与CRP相关(β=1.54e-03-mg/L per mg voriconazole,SE=2.79E-04-mg/L per mg voriconazole,p=5.49e-08),炎症时浓度更高。
- 炎症增加超治疗浓度并减少亚治疗浓度(p=0.0080)。
- 中代谢者炎症时超治疗浓度33% vs 无炎症3%(n=18 vs n=31),快代谢者15% vs 0%(n=20 vs n=28),p=0.02。
- 纵向亚组(n=25)中浓度随炎症状态(炎症前、中、后)变化。
关键数值与推荐
- 炎症定义为CRP≥10 mg/L。
- 中代谢者炎症时超治疗浓度33% vs 无炎症3%;快代谢者15% vs 0%(p=0.02)。
临床怎么用
- 对HSCT受者使用伏立康唑时,应结合CYP2C19预测代谢表型和CRP评估暴露风险。
- 中代谢和快代谢者在炎症期应加强TDM,以降低超治疗浓度风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Voriconazole is commonly used to prevent fungal infections after haematopoietic stem cell transplantation (HSCT). Although its metabolism is influenced by CYP2C19 genetics and inflammation, their combined effect is rarely considered in clinical practice, and integrated analyses remain limited. METHODS: We retrospectively analysed how inflammation and CYP2C19-predicted drug-metaboliser phenotypes affect voriconazole exposure and therapeutic range attainment in 126 HSCT patients. C-reactive protein (CRP) ≥ 10 mg/L defined inflammation. A linear mixed model (LMM) assessed associations between dose-corrected voriconazole concentrations, inflammation and CYP2C19-predicted drug-metaboliser phenotype. RESULTS: Dose-corrected voriconazole trough concentrations were associated with CYP2C19-predicted drug-metaboliser phenotype (LMM p = <2e-16, effect size of CYP2C19-phenotype: β = -5.99e-02-mg/L per mg voriconazole, standard error (SE) = 2.75e-02-mg/L per mg voriconazole, p = 0.0315; effect size of CRP: β = 1.54e-03-mg/L per mg voriconazole, SE = 2.79E-04-mg/L per mg voriconazole, p = 5.49e-08) and were higher during inflammation. Inflammation increased supra-therapeutic concentrations and reduced subtherapeutic levels (p = 0.0080). This effect was most pronounced for intermediate metabolisers (n = 18 with and n = 31 without inflammation) and rapid metabolisers (n = 20 with and n = 28 without inflammation), with supra-therapeutic concentration of 33% vs. 3%, and 15% vs. 0%, respectively (p = 0.02). Finally, in a longitudinal subset (n = 25), concentrations tracked inflammatory status across prior-, during and post-inflammation timepoints. CONCLUSIONS: This study demonstrates inflammation and CYP2C19 genotype jointly influence voriconazole exposure and target attainment in clinical practice. These findings support intensified therapeutic drug monitoring with concurrent CRP assessment, particularly for intermediate and rapid metabolisers, to reduce the risk of supra-therapeutic voriconazole concentrations during inflammation.
引用
- Klomp SD, Manson ML, Guchelaar HJ, et al. Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients. Br J Clin Pharmacol. 2026. PMID: 41766069. doi:10.1002/bcp.70501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。